Telix Pharmaceuticals (TLX) Earnings: 3Q Illuccix US Revenue Hits A$195M, Forecasts Strong Year-End Growth

Telix Pharmaceuticals on Smartkarma

Analyst coverage on Smartkarma for Telix Pharmaceuticals has been quite positive. Tina Banerjee highlighted in a report that Telix reported a 65% year-over-year revenue growth in 1H24, driven by strong sales of Illuccix in the U.S. This led to a net profit of A$29.7M. The company expects further revenue growth of 48–54% for the full year 2024, showing confidence in its future prospects.

Additionally, Janaghan Jeyakumar, CFA, discussed potential changes in the ASX indices impacting various companies, indicating the dynamic nature of the Australian market. Meanwhile, Clarence Chu pointed out Telix’s plan to raise around US$190m through a US ADS listing, aiming to triple its cash base, demonstrating the company’s ambitions for expansion and growth.

A look at Telix Pharmaceuticals Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Analysts assessing Telix Pharmaceuticals‘ long-term outlook indicate a promising future ahead. With a remarkable Smart Score of 5 for both Growth and Resilience, the company is expected to see significant expansion and demonstrate strong ability to withstand challenges. Furthermore, Telix Pharmaceuticals also received a high score of 5 for Momentum, suggesting a positive trajectory in the market. Despite a lower score in Value at 2 and no current dividends, the company’s focus on innovative molecularly-targeted radiation therapy for cancer treatment positions it well for continued success.

Telix Pharmaceuticals Limited, a biotechnology company, is dedicated to developing and commercializing advanced therapies for various cancers such as prostate, renal, and brain cancer. With a global reach to serve patients worldwide, Telix Pharmaceuticals‘ focus on molecularly-targeted radiation therapy sets it apart as a leader in the field. The company’s impressive Smart Scores for Growth, Resilience, and Momentum reflect a promising outlook for its future endeavors in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma